CBIO
Crescent Biopharma
CBIO
CBIO
49 hedge funds and large institutions have $52.1M invested in Crescent Biopharma in 2023 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 8 increasing their positions, 17 reducing their positions, and 11 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
less ownership
Funds ownership: →
less funds holding
Funds holding: →
less capital invested
Capital invested by funds: $ → $
53% less repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 17
55% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 11
Holders
49
Holding in Top 10
–
Calls
$389K
Puts
$31K
Top Buyers
| 1 | +$161K | |
| 2 | +$141K | |
| 3 | +$128K | |
| 4 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$54.5K |
| 5 |
ACP
Acuta Capital Partners
Redwood City,
California
|
+$41.3K |
Top Sellers
| 1 | -$458K | |
| 2 | -$348K | |
| 3 | -$248K | |
| 4 |
Truist Financial
Charlotte,
North Carolina
|
-$176K |
| 5 |
Two Sigma Investments
New York
|
-$113K |